Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

A novel chemogenetics tool for electrical modulation of stem cell-derived cardiomyocyte therapies

EF 2024-25

Résumé
Heart transplantation is currently the only available treatment to replace damaged heart muscle after a heart attack, but the limited supply of donor hearts presents a critical challenge. Pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) could offer a promising alternative therapy to address this unmet need. My research in the Laflamme Laboratory focuses on two of the major challenges to the clinical translation of hPSC-CM regenerative therapies: (1) strengthening our understanding of the mechanisms by which hPSC-CM grafts improve heart function after injury and (2) developing a safety mechanism against transient arrhythmias that can occur in the first few weeks after hPSC-CM transplantation. Our lab does this by employing fusion proteins of ion channels and unique drug receptors that can be used to modulate cell electrical activity on demand. This work aims to improve our understanding of the mechanisms of hPSC-CM cell therapy and create a safeguard against arrhythmogenic side effects. These insights will have implications for the design of future pre-clinical and clinical trials of hPSC-CM therapies.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
529971
Name
Suma Melissa
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A novel chemogenetics tool for electrical modulation of stem cell-derived cardiomyocyte therapies
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Arrhythmias; Cardiomyocytes; Cell Therapies; Chemogenetics; Heart Failure; Hpsc-Cm Transplantation; Myocardial Infarction; Pluripotent Stem Cell-Derived Cardiomyocytes; Pluripotent Stem Cells; Regenerative Medicine
Abstract
Heart transplantation is currently the only available treatment to replace damaged heart muscle after a heart attack, but the limited supply of donor hearts presents a critical challenge. Pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) could offer a promising alternative therapy to address this unmet need. My research in the Laflamme Laboratory focuses on two of the major challenges to the clinical translation of hPSC-CM regenerative therapies: (1) strengthening our understanding of the mechanisms by which hPSC-CM grafts improve heart function after injury and (2) developing a safety mechanism against transient arrhythmias that can occur in the first few weeks after hPSC-CM transplantation. Our lab does this by employing fusion proteins of ion channels and unique drug receptors that can be used to modulate cell electrical activity on demand. This work aims to improve our understanding of the mechanisms of hPSC-CM cell therapy and create a safeguard against arrhythmogenic side effects. These insights will have implications for the design of future pre-clinical and clinical trials of hPSC-CM therapies.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Suma, Melissa
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~